MDXG

In April 2026, MiMedx eliminated the Chief Operating Officer (COO) role as a cost-saving initiative, and the stock reached its 52-week low of $3.025. Q1 2026 results were negatively impacted by changes in Medicare wound reimbursement, lower pricing, and new pre-authorization processes, leading to reduced orders, a Medicare Administrative Contractor halting submissions, and a cut to annual guidance. For Q2 2026, the company reported earnings of -$0.10 per share, missing estimates, and a net income of -$14.84 million, though revenue of $64.36 million exceeded estimates. In September 2026, MiMedx announced a favorable federal court ruling regarding the FDA regulatory classification of its AXIOFILL® product. By September 29, 2026, the stock price was $4.66 per share, representing a 33.17% decline from the previous year.